Marie E. Wood, University of Vermont, Burlington, VT; Pamela Kadlubek, Trang H. Pham, and Dana S. Wollins, American Society of Clinical Oncology, Alexandria, VA; Karen H. Lu, MD Anderson Cancer Center, Houston, TX; Jeffrey N. Weitzel, City of Hope, Duarte, CA; Michael N. Neuss, Vanderbilt- Ingram Cancer Center, Nashville, TN; and Kevin S. Hughes, Avon Comprehensive Breast Evaluation Center, Mass General Hospital, Boston, MA.
J Clin Oncol. 2014 Mar 10;32(8):824-9. doi: 10.1200/JCO.2013.51.4661. Epub 2014 Feb 3.
Family history of cancer (CFH) is important for identifying individuals to receive genetic counseling/testing (GC/GT). Prior studies have demonstrated low rates of family history documentation and referral for GC/GT.
CFH quality and GC/GT practices for patients with breast (BC) or colon cancer (CRC) were assessed in 271 practices participating in the American Society of Clinical Oncology Quality Oncology Practice Initiative in fall 2011.
A total of 212 practices completed measures regarding CFH and GC/GT practices for 10,466 patients; 77.4% of all medical records reviewed documented presence or absence of CFH in first-degree relatives, and 61.5% of medical records documented presence or absence of CFH in second-degree relatives, with significantly higher documentation for patients with BC compared with CRC. Age at diagnosis was documented for all relatives with cancer in 30.7% of medical records (BC, 45.2%; CRC, 35.4%; P ≤ .001). Referall for GC/GT occurred in 22.1% of all patients with BC or CRC. Of patients with increased risk for hereditary cancer, 52.2% of patients with BC and 26.4% of those with CRC were referred for GC/GT. When genetic testing was performed, consent was documented 77.7% of the time, and discussion of results was documented 78.8% of the time.
We identified low rates of complete CFH documentation and low rates of referral for those with BC or CRC meeting guidelines for referral among US oncologists. Documentation and referral were greater for patients with BC compared with CRC. Education and support regarding the importance of accurate CFH and the benefits of proactive high-risk patient management are clearly needed.
癌症家族史(CFH)对于确定接受遗传咨询/检测(GC/GT)的个体非常重要。先前的研究表明,CFH 的记录和 GC/GT 的转介率较低。
2011 年秋季,271 家参与美国临床肿瘤学会质量肿瘤学实践倡议的实践评估了乳腺癌(BC)或结肠癌(CRC)患者的 CFH 质量和 GC/GT 实践。
共有 212 家实践完成了关于 CFH 和 GC/GT 实践的措施,涉及 10466 名患者;77.4%的病历记录了一级亲属 CFH 的存在或缺失,61.5%的病历记录了二级亲属 CFH 的存在或缺失,BC 患者的记录明显高于 CRC 患者。30.7%的病历记录了所有有癌症的亲属的发病年龄(BC,45.2%;CRC,35.4%;P ≤.001)。BC 或 CRC 所有患者中有 22.1%被转介进行 GC/GT。在遗传性癌症风险增加的患者中,52.2%的 BC 患者和 26.4%的 CRC 患者被转介进行 GC/GT。当进行基因检测时,77.7%的时间记录了同意书,78.8%的时间记录了结果讨论。
我们发现美国肿瘤学家对符合转介指南的 BC 或 CRC 患者的 CFH 完整记录率和转介率较低。与 CRC 相比,BC 患者的记录和转介更多。显然需要对准确记录 CFH 的重要性和积极管理高危患者的好处进行教育和支持。